.avif)
Huge congratulations to Cameron Pye and the entire team at Unnatural Products Inc. (UNP) on their definitive agreement to be acquired by argenx. The deal includes $550 million upfront in cash plus up to $595 million in development and regulatory milestones, for total potential consideration of up to approximately $1.15 billion. It is expected to close by the end of the year.
It's a landmark moment for UNP and a strong signal of where drug discovery is heading. It also builds on a real relationship: the two companies have worked together for more than two years, and argenx already held a minority stake in UNP. UNP's team will keep operating from Santa Cruz, California, which becomes argenx's home for peptide discovery. argenx is lucky to bring this incredible gem of a team and company into the fold.
Going after the "undruggable"
Many high-value disease targets have long been considered difficult, or even impossible, to drug. Conventional small molecules often can't bind them well, and the options that can tend to require injections or frequent dosing.
Macrocyclic peptides offer a different path: designed well, they can bind difficult targets with precision while remaining permeable enough to be taken as a pill. argenx sees UNP's peptide capabilities as highly complementary to its own antibody engineering, opening the door to oral and long-acting medicines for people living with serious immune-mediated diseases. Designing macrocycles that do all of this at once has always been the hard part, and it's exactly the problem UNP set out to solve.
A founder who embodies what we look for
Cam is one of those incredibly special founders who embody everything you'd hope for in a leader. His technical depth is the foundation. UNP was founded by macrocycle pioneers whose academic work helped explain how nature's macrocycles work, and its platform pairs parallel experimentation with machine learning to generate thousands of incredibly small, precise, permeable, and orally bioavailable molecules aimed at targets the industry had largely written off.
But technical excellence alone doesn't build a company. Cam is one of the most fiercely determined people I know. He is also cool as a cucumber, juking and jiving through the rapid shifts in both biotech and AI without losing sight of the mission. That combination of rigor, grit, and composure is rare, and it is a big part of why UNP got here.
The next generation of AI-native drug development
UNP represents what we believe the next generation of biotech looks like. Rather than bolting AI onto a traditional discovery process, the company was built around machine learning paired with parallel experimentation, using that combination to explore chemical space far faster and more broadly than conventional methods allow.
A deal of this scale, with $550 million upfront, is a vote of confidence not just in UNP's molecules but in the AI-native model itself. It shows this approach can produce a discovery engine that a leading immunology company wants to make its own.
An utter pleasure
At Wing, we partner with founders building at the frontier, and it has been an utter pleasure to work alongside Cam and the UNP team in bringing his vision to reality. We're proud of what they've built and excited to see UNP keep leading its discovery work from Santa Cruz as part of argenx, advancing new medicines toward patients who have been waiting a long time for better options.
Congratulations, Cam and team. Well deserved.
Read argenx's full announcement here.
